Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO
Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrolizumab, in patients with micro...